390 related articles for article (PubMed ID: 26038315)
61. Architecture of TFIIIC and its role in RNA polymerase III pre-initiation complex assembly.
Male G; von Appen A; Glatt S; Taylor NM; Cristovao M; Groetsch H; Beck M; Müller CW
Nat Commun; 2015 Jun; 6():7387. PubMed ID: 26060179
[TBL] [Abstract][Full Text] [Related]
62. Genome-wide occupancy profile of the RNA polymerase III machinery in Saccharomyces cerevisiae reveals loci with incomplete transcription complexes.
Moqtaderi Z; Struhl K
Mol Cell Biol; 2004 May; 24(10):4118-27. PubMed ID: 15121834
[TBL] [Abstract][Full Text] [Related]
63. TFIIIC binding sites function as both heterochromatin barriers and chromatin insulators in Saccharomyces cerevisiae.
Simms TA; Dugas SL; Gremillion JC; Ibos ME; Dandurand MN; Toliver TT; Edwards DJ; Donze D
Eukaryot Cell; 2008 Dec; 7(12):2078-86. PubMed ID: 18849469
[TBL] [Abstract][Full Text] [Related]
64. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
[TBL] [Abstract][Full Text] [Related]
65. The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells.
Streubel G; Watson A; Jammula SG; Scelfo A; Fitzpatrick DJ; Oliviero G; McCole R; Conway E; Glancy E; Negri GL; Dillon E; Wynne K; Pasini D; Krogan NJ; Bracken AP; Cagney G
Mol Cell; 2018 Apr; 70(2):371-379.e5. PubMed ID: 29606589
[TBL] [Abstract][Full Text] [Related]
66. Spatial organization of transcription by RNA polymerase III.
Haeusler RA; Engelke DR
Nucleic Acids Res; 2006; 34(17):4826-36. PubMed ID: 16971453
[TBL] [Abstract][Full Text] [Related]
67. Mutations and deletions of PRC2 in prostate cancer.
Jain P; Di Croce L
Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
[TBL] [Abstract][Full Text] [Related]
68. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
[TBL] [Abstract][Full Text] [Related]
69. ZSCAN5B and primate-specific paralogs bind RNA polymerase III genes and extra-TFIIIC (ETC) sites to modulate mitotic progression.
Sun Y; Zhang H; Kazemian M; Troy JM; Seward C; Lu X; Stubbs L
Oncotarget; 2016 Nov; 7(45):72571-72592. PubMed ID: 27732952
[TBL] [Abstract][Full Text] [Related]
70. TFIIIC Binding to Alu Elements Controls Gene Expression via Chromatin Looping and Histone Acetylation.
Ferrari R; de Llobet Cucalon LI; Di Vona C; Le Dilly F; Vidal E; Lioutas A; Oliete JQ; Jochem L; Cutts E; Dieci G; Vannini A; Teichmann M; de la Luna S; Beato M
Mol Cell; 2020 Feb; 77(3):475-487.e11. PubMed ID: 31759822
[TBL] [Abstract][Full Text] [Related]
71. Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression.
Wu G; Wang Q; Wang D; Xiong F; Liu W; Chen J; Wang B; Huang W; Wang X; Chen Y
Clin Transl Med; 2023 Dec; 13(12):e1502. PubMed ID: 38050190
[TBL] [Abstract][Full Text] [Related]
72. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT
Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601
[TBL] [Abstract][Full Text] [Related]
73. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
74. Polycomb repressive complex 2 epigenomic signature defines age-associated hypermethylation and gene expression changes.
Dozmorov MG
Epigenetics; 2015; 10(6):484-95. PubMed ID: 25880792
[TBL] [Abstract][Full Text] [Related]
75. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
76. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Wang C; Liu Z; Woo CW; Li Z; Wang L; Wei JS; Marquez VE; Bates SE; Jin Q; Khan J; Ge K; Thiele CJ
Cancer Res; 2012 Jan; 72(1):315-24. PubMed ID: 22068036
[TBL] [Abstract][Full Text] [Related]
77. Nhp6, an HMG1 protein, functions in SNR6 transcription by RNA polymerase III in S. cerevisiae.
Kruppa M; Moir RD; Kolodrubetz D; Willis IM
Mol Cell; 2001 Feb; 7(2):309-18. PubMed ID: 11239460
[TBL] [Abstract][Full Text] [Related]
78. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
79. O-GlcNAcylation regulates EZH2 protein stability and function.
Chu CS; Lo PW; Yeh YH; Hsu PH; Peng SH; Teng YC; Kang ML; Wong CH; Juan LJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(4):1355-60. PubMed ID: 24474760
[TBL] [Abstract][Full Text] [Related]
80. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
Gautam N; Kaur M; Kaur S
J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
